Over the past twenty-five years, Obesity rates have spiraled to the level nearly 5 hundred million individuals worldwide. The United States leads the world, with a startling 31 % of the population being termed obese.
The medical costs directly associated with obesity are nearly impossible to calculate, simply because multiple health problems and risks are associated with the condition. The preventable health problems associated with obesity include high blood pressure, stroke, heart attack and diabetes.
The good news is that pharmaceutical Company, Vivus, has an innovative new product that is designed to foster significant weight loss in obese patients. This product has recently announced approval for this medication named Qsymia, commonly termed as the weight loss pill.
The fact that the FDA is moving to approve a weight loss drug this year, is notably significant. The Food and drug administration has not approved a diet medication in the past decade. Qsymia is a combination drug. In other words, it is actually two separate drugs working together in one pill. Both drugs already have been known to enjoy success in the area of weight loss therapy.
This weight loss drug among other things, is approved under strenuous clinical study. Patients were monitored while on Qsymia for 12 consecutive months. In one study, patients lost an average of 6.7 per cent of body weight, while in the other, patients lost an average of 8.9 per cent. Patients on the highest dosages reported significant body weight loss as high as 22 pounds.
The two drugs that combine to make Qsymia are Phentermine and Topiramate. Phentermine is a stimulant and appetite suppressant, long acknowledged for its advantage for weight loss. Topiramate is an anti-consultant, which also makes people feel more satisfied after eating. Researchers have determined that the innovation of Qsymia is that it targets more than one component that causes people to overeat.
Research also reveals that Qsymia usage correlates to lower blood pressure and the easement of other cardiovascular risks associated with obesity. There is also reported improvement in the sleep disorder known as sleep apnea.
There are certain restrictions that are assigned to Qsymia by the FDA. For example, it is only approved for use in adults. It is also restricted to use only by patients who are diagnosed as clinically obese. In addition, pregnant women are prohibited from using it. This drug must be prescribed and monitored by a physician.
Physicians and clinics on the leading edge of practice have adapted their offerings to their patients based on the results of these studies. They see this as another tool to wage battle against obesity. One such company; Equilibrium Weight loss and Longevity offers Qsymia as part of a comprehensive line of weight loss protocols.
The medical costs directly associated with obesity are nearly impossible to calculate, simply because multiple health problems and risks are associated with the condition. The preventable health problems associated with obesity include high blood pressure, stroke, heart attack and diabetes.
The good news is that pharmaceutical Company, Vivus, has an innovative new product that is designed to foster significant weight loss in obese patients. This product has recently announced approval for this medication named Qsymia, commonly termed as the weight loss pill.
The fact that the FDA is moving to approve a weight loss drug this year, is notably significant. The Food and drug administration has not approved a diet medication in the past decade. Qsymia is a combination drug. In other words, it is actually two separate drugs working together in one pill. Both drugs already have been known to enjoy success in the area of weight loss therapy.
This weight loss drug among other things, is approved under strenuous clinical study. Patients were monitored while on Qsymia for 12 consecutive months. In one study, patients lost an average of 6.7 per cent of body weight, while in the other, patients lost an average of 8.9 per cent. Patients on the highest dosages reported significant body weight loss as high as 22 pounds.
The two drugs that combine to make Qsymia are Phentermine and Topiramate. Phentermine is a stimulant and appetite suppressant, long acknowledged for its advantage for weight loss. Topiramate is an anti-consultant, which also makes people feel more satisfied after eating. Researchers have determined that the innovation of Qsymia is that it targets more than one component that causes people to overeat.
Research also reveals that Qsymia usage correlates to lower blood pressure and the easement of other cardiovascular risks associated with obesity. There is also reported improvement in the sleep disorder known as sleep apnea.
There are certain restrictions that are assigned to Qsymia by the FDA. For example, it is only approved for use in adults. It is also restricted to use only by patients who are diagnosed as clinically obese. In addition, pregnant women are prohibited from using it. This drug must be prescribed and monitored by a physician.
Physicians and clinics on the leading edge of practice have adapted their offerings to their patients based on the results of these studies. They see this as another tool to wage battle against obesity. One such company; Equilibrium Weight loss and Longevity offers Qsymia as part of a comprehensive line of weight loss protocols.
About the Author:
Are you looking to find out if Qsymia Capsules are available around you? We all will have to get a prescription to get the Qsymia diet pills
